Still Looking For The Off-The-Shelf Breakthrough, Allogene Touts Myeloma CAR-T Candidate
Raises Hopes Of Challenging Abecma And Carvykti
While a cloud hangs over the future of its CD19-targeting allogeneic candidate, points to preclinical potential of superior efficacy for ALLO-715.
You may also be interested in...
The company aims to file for desmoid tumors in the second half of 2022, but it has more than half a dozen combination programs with BCMA-targeting therapies in multiple myeloma.
The company is winding down its autologous myeloma CAR-T program as competition in that market heats up and interest in off-the-shelf CAR-Ts grows.
Several big pharma companies may be interested in buying Mirati, but could baulk at paying up to $12bn for its as-yet-unproven oncology portfolio.